In Large Prospective Study, NCI to Test Oncotype s Ability to Predict Chemo Response in Breast Cancer | GenomeWeb

The US National Cancer Institute has begun enrolling around 4,390 patients with breast cancer in a large prospective trial to test the ability of Genomic Health's Oncotype Dx assay to predict their response to chemotherapy.

The Trial Assigning Individualized Options for Treatment, or TAILORx, will be the first prospective study examining chemotherapy prediction with Oncotype, and it follows on the heels of a study associating the test's recurrence score with a likely benefit of chemotherapy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.